Analyst Ratings for [VOR] Vor Biopharma Inc

VOR Vor Biopharma Inc

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

7/26/22	Initiated	Outperform	X
VOR Vor Biopharma Wedbush
$18
4/27/22	Initiated	Neutral	X
VOR Vor Biopharma Goldman
$6
12/17/21	Initiated	Buy	X
VOR Vor Biopharma H.C. Wainwright
$26
12/2/21	Initiated	Outperform	X
VOR Vor Biopharma Oppenheimer
$30
10/19/21	Initiated	Mkt Outperform	X
VOR Vor Biopharma JMP Securities
$40
3/25/21	Initiated	Buy	X
VOR Vor Biopharma B. Riley Securities
$60
3/3/21	Initiated	Overweight	X
VOR Vor Biopharma Barclays
$56
3/3/21	Initiated	Outperform	X
VOR Vor Biopharma Evercore ISI
$48
3/2/21	Initiated	Sell	X
VOR Vor Biopharma Goldman
$19
3/2/21	Initiated	Buy	X
VOR Vor Biopharma Stifel
$58